-transparent.png){kind=logo}
Plasma concentrations of levodopa were determined after therapeutic oral levodopa-carbidopa doses. The wide fluctuations observed in plasma levodopa levels could be considerably reduced by the addition of a slow release levodopa preparation. This kind of combination medication was given to 15 parkinsonian patients, whose earlier therapy had proved inadequate. With the combination medication, levodopa-carbidopa, on an average 420 mg/42 mg combined with 950 mg of levodopa in slow release form, a statistically significant improvement in parkinsonian signs could be achieved without any worsening of the side effects. The results suggest that parkinsonian patients may tolerate much higher daily levodopa doses if the fluctuations in plasma levels of the drug can be diminished.
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
December 1974,
The Medical annals of the District of Columbia,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
June 1972,
Canadian Medical Association journal,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
March 1974,
The Medical journal of Australia,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
January 1976,
Neurologia, neurocirugia, psiquiatria,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
February 1973,
Journal of neurology, neurosurgery, and psychiatry,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
December 1975,
Journal of neurology,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
October 1975,
Neurology,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
January 1991,
European journal of clinical pharmacology,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
January 1987,
European neurology,
A Saarinen, and
V V Myllylä, and
O Tokola, and
E Hokkanen
January 1978,
Current medical research and opinion,
